An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs RG 7880 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech
- 26 Jul 2017 Planned End Date changed from 1 Oct 2017 to 27 Oct 2017.
- 26 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 27 Oct 2017.
- 15 Jul 2016 Status changed from not yet recruiting to recruiting.